Abstract
The treatment of immune-mediated inflammatory diseases (IMIDs) has dramatically improved over the last two decades by the development of a series of targeted biological therapies. This paper focuses on new developments in the treatment of IMIDs. In particular, we discuss how different ways of targeting the same mediators can lead to different efficacy and safety profiles, using B cell targeting as example. In addition, we discuss the emerging field of ‘small molecules’ that target specifically intracellular processes related to cytokine signaling, cell activation, cell migration, and other processes relevant to tissue inflammation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581
Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232
Looney RJ, Anolik J, Sanz I (2010) A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 20:1–10
Looney RJ, Anolik JH, Campbell D et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580–2589
Smith V, Piette Y, van Praet JT et al (2013) Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 40:52–57
Meijer JM, Meiners PM, Vissink A et al (2010) Effectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:960–968
Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688
Bluml S, McKeever K, Ettinger R, Smolen J, Herbst R (2013) B-cell targeted therapeutics in clinical development. Arthritis Res Ther 15(Suppl 1):S4
Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425–437
Castillo J, Milani C, Mendez-Allwood D (2009) Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs 18:491–500
Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ (2011) Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 70:2119–2125
Ostergaard M, Baslund B, Rigby W et al (2010) Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 62:2227–2238
Sorensen PS, Lisby S, Grove R et al (2014) Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 82:573–581
Kausar F, Mustafa K, Sweis G et al (2009) Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther 9:889–895
Rigby W, Tony HP, Oelke K et al (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64:350–359
Tak PP, Mease PJ, Genovese MC et al (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64:360–370
Mysler EF, Spindler AJ, Guzman R et al (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65:2368–2379
Kappos L, Li D, Calabresi PA et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378:1779–1787
Liebman HA, Saleh MN, Bussel JB et al (2013) Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. Br J Haematol 162:693–701
Goldenberg DM, Morschhauser F, Wegener WA (2010) Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 51:747–755
Tedder TF (2009) CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 5:572–577
Yazawa N, Hamaguchi Y, Poe JC, Tedder TF (2005) Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci U S A 102:15178–15183
Herbst R, Wang Y, Gallagher S et al (2010) B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 335:213–222
Deiss A, Brecht I, Haarmann A, Buttmann M (2013) Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother 13:313–335
Dorner T, Shock A, Smith KG (2012) CD22 and autoimmune disease. Int Rev Immunol 31:363–378
Tedder TF, Poe JC, Haas KM (2005) CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88:1–50
Carnahan J, Stein R, Qu Z et al (2007) Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44:1331–1341
Steinfeld SD, Tant L, Burmester GR et al (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 8:R129
Wallace DJ, Kalunian K, Petri MA et al (2014) Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73:183–190
Wallace DJ, Gordon C, Strand V et al (2013) Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) 52:1313–1322
Avery DT, Kalled SL, Ellyard JI et al (2003) BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 112:286–297
Baker KP, Edwards BM, Main SH et al (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48:3253–3265
Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731
Stohl W, Merrill JT, McKay JD et al (2013) Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol 40:579–589
Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F (2013) The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 24:203–215
Davidson A (2010) Targeting BAFF in autoimmunity. Curr Opin Immunol 22:732–739
Genovese MC, Lee E, Satterwhite J et al (2013) A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 72:1453–1460
Stohl W (2014) Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets 18:473–489
Gensicke H, Leppert D, Yaldizli O et al (2012) Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs 26:11–37
Gatto B (2008) Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr Opin Investig Drugs 9:1216–1227
Schneider P (2005) The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 17:282–289
Dall’Era M, Chakravarty E, Wallace D et al (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56:4142–4150
van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J (2011) Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 63:1782–1792
Genovese MC, Kinnman N, de La BG, Pena RC, Tak PP (2011) Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 63:1793–1803
Kappos L, Hartung HP, Freedman MS et al (2014) Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol 13:353–363
Fernandez L, Salinas GF, Rocha C et al (2013) The TNF family member APRIL dampens collagen-induced arthritis. Ann Rheum Dis 72:1367–1374
Arthur JS, Ley SC (2013) Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 13:679–692
Hammaker D, Firestein GS (2010) “Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis 69(Suppl 1):i77–i82
Hommes D, van den Blink B, Plasse T et al (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease. Gastroenterology 122:7–14
Dotan I, Rachmilewitz D, Schreiber S et al (2010) A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn’s disease. Gut 59:760–766
Salh B (2007) c-Jun N-terminal kinases as potential therapeutic targets. Expert Opin Ther Targets 11:1339–1353
Guma M, Firestein GS (2012) c-Jun N-terminal kinase in inflammation and rheumatic diseases. Open Rheumatol J 6:220–231
Han Z, Boyle DL, Chang L et al (2001) c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108:73–81
Hayden MS, Ghosh S (2011) NF-kappaB in immunobiology. Cell Res 21:223–244
Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27:693–733
Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:7–11
Tak PP, Gerlag DM, Aupperle KR et al (2001) Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 44:1897–1907
Tas SW, Vervoordeldonk MJ, Hajji N, May MJ, Ghosh S, Tak PP (2006) Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther 8:R86
Kwak JH, Jung JK, Lee H (2011) Nuclear factor-kappa B inhibitors; a patent review (2006-2010). Expert Opin Ther Pat 21:1897–1910
Sehnert B, Burkhardt H, Wessels JT et al (2013) NF-kappaB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-kappaB in immune-mediated diseases. Proc Natl Acad Sci U S A 110:16556–16561
Sun SC (2012) The noncanonical NF-kappaB pathway. Immunol Rev 246:125–140
Noort AR, van Zoest KP, Weijers EM et al (2014) NF-kappaB inducing kinase is a key regulator of inflammation-induced and tumor-associated angiogenesis. J Pathol 234:375
Li K, McGee LR, Fisher B et al (2013) Inhibiting NF-kappaB-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures. Bioorg Med Chem Lett 23:1238–1244
Shuai K, Liu B (2003) Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3:900–911
Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P (2008) Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 10:R14
Changelian PS, Flanagan ME, Ball DJ et al (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302:875–878
Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:495–507
Burmester GR, Blanco R, Charles-Schoeman C et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451–460
Sandborn WJ, Ghosh S, Panes J et al (2012) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367:616–624
Boy MG, Wang C, Wilkinson BE et al (2009) Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 129:2299–2302
Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509
Baeten DL, Kuchroo VK (2013) How Cytokine networks fuel inflammation: interleukin-17 and a tale of two autoimmune diseases. Nat Med 19:824–825
Yeremenko N, Paramarta JE, Baeten D (2014) The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol 26:361–370
Byrne H, Conroy PJ, Whisstock JC, O’Kennedy RJ (2013) A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 31:621–632
Rossi EA, Chang CH, Goldenberg DM (2014) Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus. PLoS One 9:e98315
Grabiec AM, Reedquist KA (2013) The ascent of acetylation in the epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 9:311–318
Vojinovic J, Damjanov N, D’Urzo C et al (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 63:1452–1458
Acknowledgements
SWT is supported by a VENI grant and a Clinical Fellowship from the Netherlands Organization for Scientific Research (NWO/ZonMw), and grants from the Dutch Arthritis Foundation. DLB is supported by a VICI grant from the Netherlands Organization for Scientific Research (NWO), and grants from the Dutch Arthritis Foundation.
Disclosure of conflicts of interest: The authors declare no competing financial interests.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Tas, S.W., Baeten, D.L.P. (2016). Recent Advances in the Treatment of Immune-Mediated Inflammatory Diseases. In: Cuturi, M., Anegon, I. (eds) Suppression and Regulation of Immune Responses. Methods in Molecular Biology, vol 1371. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3139-2_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3139-2_9
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3138-5
Online ISBN: 978-1-4939-3139-2
eBook Packages: Springer Protocols